285979-06-8

Basic information

• Product Name: 1H-Benzimidazole, 5-bromo-1-(triphenylmethyl)-
• CAS NO: 285979-06-8
• Molecular Formula: C26H19BrN2
• Molecular Weight: 439.354
• Mol File: 285979-06-8.mol

Chemical Properties

• CAS DataBase Reference: 1H-Benzimidazole, 5-bromo-1-(triphenylmethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Benzimidazole, 5-bromo-1-(triphenylmethyl)-(285979-06-8)
• EPA Substance Registry System: 1H-Benzimidazole, 5-bromo-1-(triphenylmethyl)-(285979-06-8)

Safety Data

• Hazardous Substances Data: 285979-06-8(Hazardous Substances Data)

Upstream product

• 76-83-5 trityl chloride 
• 4887-88-1 6-bromo-1H-benzo[d]imidazole 
• 4887-88-1 5-bromo-1H-benzo[d]imidazole 

Downstream Products

• 885066-54-6 1-trityl-1H-benzoimidazol-5-yl-boronic acid 

Relevant articles and documents

Pd(0) amination of benzimidazoles as an efficient method towards new (benzimidazolyl)piperazines with high affinity for the 5-HT(1A) receptor

New (benzimidazolyl)amines have been synthesized from 4- and 6- bromobenzimidazole derivatives via palladium-mediated amination reactions. Among them, (benzimidazol-4(7)-yl)piperazine derivatives have been shown to be a new family of high affinity 5-HT(1A) receptor ligands. (C) 2000 Elsevier Science Ltd.

2-ARYLSULFONAMIDO-N-ARYLACETAMIDE DERIVATIZED STAT3 INHIBITORS

The present disclosure provides pharmaceutical compositions comprising 2-arylsulfonamido-N-arylacetamide derivatized Stat3 inhibitors and certain pharmaceutically acceptable salts thereof, and methods of their use.

NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS

This invention relates to novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy.

Synthesis of new (benzimidazolyl)piperazines with affinity for the 5- HT(1A) receptor via Pd(0) amination of bromobenzimidazoles

The synthesis of a new family of (benzimidazolyl)piperazines has been developed through Pd(0) mediated amination of 4- and 6-bromobenzimidazole derivatives. Preliminary studies showed that some of these compounds are potent 5-HT(1A) receptor ligands.